⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

December 6, 2018Antimicrobial Agents and ChemotherapyOpen Access

Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda

Erika Wallender Nan Zhang Melissa D. Conrad Abel Kakuru Mary Muhindo Patrick K. Tumwebaze Richard Kajubi Daniel J. Mota Jennifer Legac Prasanna Jagannathan Diane V. Havlir Moses R. Kamya Grant Dorsey Francesca Aweeka Philip J. Rosenthal Rada Savic

View Full Paper

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Dihydroartemisinin-piperaquine (DHA-PQ) is under study for intermittent preventive treatment during pregnancy (IPTp), but it may accelerate selection for drug resistance. Understanding the relationships between piperaquine concentration, prevention of parasitemia, and selection for decreased drug sensitivity can inform control policies and optimization of DHA-PQ dosing.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wallender et al. (2018) studied this question.

synapsesocial.com/papers/6a86fb01d08104c969cb9c8c https://doi.org/10.1128/aac.01393-18

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Effects of malaria intermittent preventive treatment with dihydroartemisinin-piperaquine on antiretroviral drug concentrations in African pregnant women living with HIVClinical Trial · 2026
2Pharmacokinetics of piperaquine and its association with intermittent malaria preventive therapy outcomes during pregnancy2024 · 4 citations
3Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan WomenOriginal Research · 2020 · 8 citations
4Population Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated MalariaOriginal Research · 2012 · 101 citations
5463. Comparative Effectiveness of Dihydroartemisinin-Piperaquine and Sulfadoxine-Pyrimethamine in Preventing Adverse Pregnancy Outcomes: A Meta-Analysis and Systematic ReviewMeta-Analysis · 2026
6Dihydroartemisinin–piperaquine plus sulfadoxine-pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomized, controlled trialRCT · 2025 · 15 citations
7Dihydroartemisinin-Piperaquine Treatment of Multidrug Resistant Falciparum and Vivax Malaria in PregnancyReview · 2014 · 48 citations
8Maternal, Fetal, and Neonatal Outcomes of Additional Dihydroartemisinin-Piperaquine to Trimethoprim-Sulfamethoxazole in Intermittent Preventive Treatment for Malaria in HIV-Positive Pregnancies: A Systematic Review and Meta-AnalysisMeta-Analysis · 2026
9Population pharmacokinetic modeling of abacavir in HIV-exposed neonates and children with HIV-1 using data from the IMPAACT 2019 and PETITE studiesAntimicrobial Agents and Chemotherapy · 2026
10Functional export of NDM-7 to outer membrane vesicles in Klebsiella pneumoniae compromises imipenem and cefiderocol activityAntimicrobial Agents and Chemotherapy · 2026

More from Antimicrobial Agents and Chemotherapy

More from Stanford University

More from University of California, San Francisco

More from Makerere University

More from Infectious Diseases Research Collaboration